Suppr超能文献

一种新型测定法,可用于高通量筛选抗老年痴呆症药物,通过实时监测 PC12 细胞增殖变化来测定其疗效。

A novel assay for high-throughput screening of anti-Alzheimer's disease drugs to determine their efficacy by real-time monitoring of changes in PC12 cell proliferation.

机构信息

Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, P.R. China.

出版信息

Int J Mol Med. 2014 Mar;33(3):543-9. doi: 10.3892/ijmm.2013.1608. Epub 2013 Dec 27.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease that is characterized by the accumulation of senile plaque and neurofibrilary tangle formation in the brain, including the cerebral cortex and hippocampus. Nowadays, the first-line treatment for AD is the application of acetylcholinesterase inhibitors. However, acetylcholinesterase inhibitors are basically anti-symptomatic for a limited aspect of AD pathology and are associated with serious side-effects. With the advantage of multiple targets, pathways and systems, Chinese herbal compounds hold promising potential for the development of drugs for the treatment of AD. Over the past few years, with the development of Chinese herbal compounds and in vitro pharmacological studies, cell-based disease models are one of the main methods used to screen Chinese herbal compounds for potential efficacy. Testing the efficacy of possible anti-Alzheimer's disease drugs and the development of new drugs are hindered by the lack of objective high-throughput screening methods. Currently, the assessment of the effects of drugs is usually made by MTT assays, involving laborious, subjective, low-throughput methods. Herein, we suggest a novel application for a real-time cell monitoring device (xCELLigence) that can simply and objectively assess the effective composition of Chinese herbal compounds by assessing amyloid-β peptide Aβ1-42-induced apoptosis in PC12 cells. We detected the proliferation and motility of the cells using a fully automated high-throughput and real-time system. We quantitatively assessed cell motility and determined the real-time IC50 values of various anti-AD drugs that intervene in several developmental stages of Aβ1-42-induced apoptosis in PC12 cells, Then, we identified the optimal time phase by curative efficacy. Our data indicate that this technique may aid in the discovery and development of novel anti-Alzheimer's disease drugs. It is possible to utilize a similar technique to measure changes in electrical impedance as cells attach and spread in a culture dish covered with a gold microelectrode array that covers approximately 80% of the area on the bottom of a well. As cells attach and spread on the electrode surface, it leads to an increase in electrical impedance of 9-12. The impedance is displayed as a dimensionless para-meter termed the cell index, which is directly proportional to the total area of tissue culture well that is covered by the cells. Hence, the cell index can be used to monitor cell adhesion, spreading, morphological variation and cell density.

摘要

阿尔茨海默病(AD)是一种神经退行性疾病,其特征是大脑中包括大脑皮层和海马体在内的部位出现老年斑和神经原纤维缠结的积累。目前,AD 的一线治疗方法是应用乙酰胆碱酯酶抑制剂。然而,乙酰胆碱酯酶抑制剂基本上只能针对 AD 病理的有限方面进行对症治疗,并且会伴随严重的副作用。由于具有多靶点、多途径和多系统的优势,中草药化合物在开发治疗 AD 的药物方面具有很大的潜力。在过去的几年中,随着中草药化合物的发展和体外药理学研究的进展,基于细胞的疾病模型已成为筛选中草药化合物潜在疗效的主要方法之一。测试可能的抗阿尔茨海默病药物的疗效和开发新药受到缺乏客观高通量筛选方法的阻碍。目前,药物作用的评估通常通过 MTT 测定法进行,该方法涉及费力、主观、低通量的方法。在此,我们建议将实时细胞监测仪(xCELLigence)用于评估中草药化合物的有效成分,通过评估 PC12 细胞中淀粉样β肽 Aβ1-42 诱导的细胞凋亡来简单而客观地评估其疗效。我们使用全自动高通量实时系统来检测细胞的增殖和迁移。我们定量评估细胞迁移,并确定各种抗 AD 药物的实时 IC50 值,这些药物干预了 Aβ1-42 诱导的 PC12 细胞凋亡的多个发育阶段,然后,通过疗效确定最佳时间阶段。我们的数据表明,该技术可能有助于发现和开发新型抗阿尔茨海默病药物。也可以使用类似的技术来测量细胞在附有金微电极阵列的培养皿中的电阻抗变化,该微电极阵列覆盖了培养孔底部约 80%的面积。当细胞附着并在电极表面扩散时,电阻抗会增加 9-12 倍。阻抗以无量纲参数细胞指数表示,其与细胞覆盖的组织培养孔总面积成正比。因此,细胞指数可用于监测细胞黏附、铺展、形态变化和细胞密度。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验